HUTCHMED (China) Limited (AIM:HCM)
208.00
+9.50 (4.79%)
At close: Dec 31, 2025
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
246.93K GBP
Profits / Employee
191.45K GBP
Market Cap
1.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | 1,280 | 427 | 50.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,382 |
HUTCHMED (China) News
- 3 days ago - HCM Gains Priority Review for New Cancer Treatment in China - GuruFocus
- 3 days ago - Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China - Nasdaq
- 3 days ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma - GlobeNewsWire
- 15 days ago - HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - GlobeNewsWire
- 17 days ago - RSI Alert: HUTCHMED (HCM) Now Oversold - Nasdaq
- 24 days ago - Hutchmed (HCM) Secures Drug Inclusion in China's Updated Reimbursement Lists - GuruFocus
- 5 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - GlobeNewsWire
- 7 weeks ago - HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM - Nasdaq